SEC Insider Transactions from Prior Stephen David.

Last updated: 2026-03-14 11:42 UTC | Total transactions: 8

Chief Strategy Officer Prior Stephen David sold AN2 Therapeutics Inc. ($ANTX) shares on the open market three times over the past year, totaling about $7,379. His most recent sale occurred on January 6, 2026. These sales rank 11,336th among 11,678 insiders in our database, where the average is $8.6 million across about 6.4 transactions. He made no open market purchases in this period.

Set Up your own filters →
Transaction Date Company Ticker Insider Name Title Transaction Type Security Shares Price Shares Owned Following Total Shares Outstanding % of Owned % of Outstanding
Jan. 5, 2026 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer S Common Stock 3604 $1.00 61,944.0000 30,276,230 5.50% 0.01%
Jan. 6, 2026 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer S Common Stock 2858 $1.01 59,086.0000 30,276,230 4.61% 0.01%
Nov. 4, 2025 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer S Common Stock 765 $1.14 65,548.0000 30,276,230 1.15% 0.00%
Feb. 26, 2025 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer A Common Stock 28000 $0.00 61,313.0000 29,828,227 84.05% 0.09%
Feb. 26, 2025 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer A Stock Option (right to buy) 56000 $0.00 56,000.0000 29,828,227 9999.99% 0.19%
Jan. 3, 2025 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer S Common Stock 2029 $1.34 33,313.0000 29,828,227 5.74% 0.01%
Nov. 4, 2024 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer A Stock Option (right to buy) 20250 $0.00 20,250.0000 29,841,169 9999.99% 0.07%
Nov. 4, 2024 AN2 Therapeutics, Inc. $ANTX Prior Stephen David Chief Strategy Officer A Common Stock 10125 $0.00 35,342.0000 29,841,169 40.15% 0.03%